Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.39 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13945390 | 0.90 | AR (0.39) | HTR2CHTR7HTR2BHTR3AHTR4 | |
| SCHEMBL8095680 | 0.90 | PDE4B (0.46) | HTR2CHTR7HTR2BHTR3AHTR4 | |
| SCHEMBL8102582 | 0.89 | DPP4 (0.49) | HTR7HTR2BHTR4CYP3A4DPP4 | |
| SCHEMBL13969375 | 0.86 | HTR1D (0.42) | HTR2CHTR7HTR2BHTR1ACYP3A4 | |
| SCHEMBL4241073 | 0.85 | CHRM4 (0.42) | CYP3A4DPP4CHRM4PDE4BACHE | |
| SCHEMBL8092993 | 0.84 | HTR2B (0.44) | HTR2CHTR7HTR2BHTR3AHTR4 | |
| SCHEMBL5526683 | 0.84 | SCN1A (0.50) | SCN1ASCN8A | |
| SCHEMBL4242392 | 0.84 | CHRM4 (0.49) | CYP3A4DPP4CHRM4 | |
| SCHEMBL8095861 | 0.83 | KCNH2 (0.41) | HTR2CHTR7HTR2BHTR3AHTR4 | |
| SCHEMBL8096573 | 0.83 | CYP3A4 (0.40) | HTR2CHTR2BCYP3A4DPP4CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | TRPV1, TRPV2, TRPA1 | HTR2C 305/4885HTR7 395/4885HTR2B 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.